Zynteglo

Aug 22, 2025

Vertex Pharmaceuticals and CRISPR Therapeutics have become the first companies to secure FDA approval for a CRISPR-based gene-editing therapy. Vertex Pharmaceuticals, in partnership with CRISPR Therapeutics, has achieved a historic milestone with the FDA approval of exagamglogene autotemcel (exa-cel, branded as ...

Jun 09, 2023

The cell and gene therapy market has seen a revolutionary transition in recent years, with advancements in scientific research and novel methods of treatment driving a rise in development activities. This has resulted in an increase in the number of cell and gene therapy choices available to patients suffering from...

May 12, 2023

By bringing life-changing benefits to people with rare diseases and cancers, cell and gene therapies are reshaping the field of medicine. These treatments have recently gained tremendous publicity for meeting long-standing unmet needs and being extremely costly. But high production costs are limiting patient access...

Jun 18, 2019

Bluebird declares the price of its gene therapy- Zynteglo Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorders in the Europe Union. The full price of Zynteglo can be dispersed out for five years, at approx...